OMERS Infrastructure’s Post

Connect with Inceptua Group at #ASCO2024 Inceptua Early Access is attending ASCO Annual Meeting, May 31 - June 4, 2024 in Chicago, IL. We’re looking forward to meet with existing, new, and potential clients and partners in the #oncology space. If you’re interested in an informal chat about #EarlyAccess and how we can help, please reach out to Paul Stanton, Sr. Director or Mark Bainbridge, Sr. Director, directly. You will also have the opportunity to meet our Executive Chairman Doug Cook, who will be attending the meeting along with the representatives from our Early Access business What is Early Access? Early Access also known as #ExpandedAccess, #ManagedAccess hashtag #CompassionateUse, or #NamedPatientSupply is a pathway for a patient with a life-threatening illness or severely debilitating disease or condition to gain access to an investigational medical product prior to approval by a regulatory authority. Inceptua’s Early Access team are experts in the strategy, design, and implementation of global early access programs. Inceptua Group - #helpingpharmahelpingpatients

ASCO 2024 is set to discuss several critical areas that are directly relevant to the daily challenges and strategic goals of Clinical Operations executives. Meet with Medelis at #ASCO24 to learn more - https://ow.ly/YOWp50RzWmz

# Only put off until tomorrow what you are willing to die having left undone ## Seize the Opportunity to Grow Your HSA with Fortress Biotech's Recent FDA Approval and Upcoming PDUFA Date! 💪💼🚀 Fortress Biotech, Inc. has recently made significant strides in the healthcare sector, capturing the attention of investors seeking to make the most of their Health Savings Accounts \(HSA\). The company announced that its revolutionary product, Emrosi, designed to treat inflammatory lesions of rosacea in adults, has received FDA approval on November 4, 2024. This approval is a significant milestone for Fortress Biotech, signaling its commitment to delivering innovative solutions that enhance wellness and improve the quality of life for patients suffering from this common skin condition. In addition to the FDA approval for Emrosi, Fortress Biotech has also disclosed an upcoming PDUFA date for cosibelimab, further bolstering investor enthusiasm. Cosibelimab is anticipated to bring new opportunities in the immunotherapy field, potentially revolutionizing treatment options for various medical conditions. While Fortress Biotech's financial results have shown a net loss, it is important to remember that investing in the healthcare industry is a long-term game. By capitalizing on burgeoning healthcare advancements, you have the power to not only grow your HSA but also support breakthrough innovations that can positively impact the lives of countless individuals. Don't let the Fear of Missing Out \(FOMO\) hold you back! Act now and explore the potential of investing in Fortress Biotech, leveraging the growth prospects offered by Emrosi's FDA approval and the upcoming PDUFA date for cosibelimab. Let your HSA flourish by investing in the future of healthcare. #hsa #investing #healthcare #health #family #wellness 📈💰💼💪❤️🏥

🚨BREAKING NEWS from GVS! 🚨 We’re thrilled to announce the agreement to acquire Haemonetics Corporation’s Whole Blood business—a strategic step forward in bolstering our presence in Transfusion Medicine! This acquisition brings a comprehensive portfolio of whole blood collection, processing, filtration, and transfusion solutions into the GVS family, aligning perfectly with our vertically integrated strategy. It also expands our footprint across developed markets like the US while enhancing our reach in emerging regions in EMEA, APAC, and LATAM. 💡 Key Highlights of the Deal Enhanced Portfolio: Adding critical blood management solutions to our offerings. Operational Synergies: Optimizing production by leveraging our facilities and economies of scale. Market Potential: Tapping into a $1 billion market driven by increasing global demand for safe, efficient blood collection and transfusion practices. Projected Growth: Expecting over $50M in additional revenue for FY 2025. Massimo Scagliarini, CEO of GVS, shared: “Following the acquisition of STT and Haemotronic, this transaction marks another step in our expansion strategy in the transfusion medicine market, that sees today only one player with a fully vertical business model. With Haemonetics’ business, GVS becomes a global and fully vertically integrated actor, adding complementary and highly synergic assets to its existing product offering and further reinforcing its leadership in the Healthcare filtration sector” We’re excited about the opportunities ahead and remain dedicated to driving innovation in transfusion medicine. Stay tuned for updates as we take this next big step! Read full press release here: https://lnkd.in/du63JvM2 #GVS #Acquisition #HealthcareInnovation #WholeBloodMarket #GlobalExpansion #TransfusionMedicine

🏥 Major Move in Healthcare! Krsnaa Diagnostics Ltd. (Formerly known as Krsnaa Diagnostics Pvt. Ltd.) Diagnostics has made a strategic investment by acquiring a stake in Apulki Healthcare Private Limited. This acquisition marks a significant step towards expanding diagnostic and healthcare services in India. 🩺💡 With both companies combining their expertise, this collaboration aims to improve access to advanced healthcare solutions, benefiting patients across the country. 📈 Read more about this exciting development in the healthcare industry: 👉 Read the full article Sushmita Panda Sakshi Kuchroo Sumana Sarkar Roshun Povaiah Syed Fazal Bari #Healthcare #Diagnostics #BusinessGrowth #KrsnaaDiagnostics #HealthcareInnovation #StrategicInvestment #IndiaBusiness #MedicalTechnology

🫀💵Great new day for the team at CorFlow as they announce €44M in new #funding toward their novel, CoFl, diagnostic and drug delivery platform for #microvascular obstruction (MVO). CorFlow’s CoFI system provides physicians with the ability to both detect and delivery therapy to life threatening MVOs in patients suffering acute #coronary events while still in the cath lab. The Series B will fund CorFlow’s MOCA II (MVO with CoFI System Assessment II) pivotal study across the US and Europe validating efficacy to diagnosis MVOs in heart attack patients post stent implementation as well as study for their adaptive therapeutic delivery platform. This latest round was co-led by Broadview Ventures Inc and Panakes Partners alongside 415 Capital, CorFlow’s initial VC investor and largest shareholder. "CorFlow’s breakthrough technology has been designed by clinicians for clinicians and we are excited to support CorFlow's mission to generate robust clinical data in order to get this much needed therapy to the patient as quickly as possible. We also are committed to supporting the emerging field of microvascular disease in general, and this oversubscribed funding round gives us options to apply the technology in new ways, and in new geographies, where patients can benefit.” - Barbara Castellano, Partner at Panakes Partners #medtechmoney #coronarydisease #venturecapital #medicalinnovation The Mullings Group

Quest Diagnostics and OhioHealth announced a definitive agreement for Quest to acquire select assets of OhioHealth’s outreach laboratory services business. The transaction will broaden access to cost-effective and innovative laboratory services in Ohio. After the acquisition’s close, providers and patients will benefit from access to Quest’s industry-leading test menu, network of patient service sites throughout the state, broad health plan coverage, and lower out-of-pocket costs for many services. Read More: https://lnkd.in/dpkFMTuq Christopher Clinton, President, OhioHealth Regional Market and former Vice President, Shared Services, Juanita Swickard, Interim Vice President, Shared Services, OhioHealth. & Jim Davis Chairman, CEO and President, Quest Diagnostics commented on the acquisition #mededgemea #QuestDiagnostics #ohiohealth #HealthcareAcquisition #labservices #MedicalTesting #healthcarenews #HealthInnovation #diagnostics #HealthcarePartnership #laboutreach

“We punch well above our weight,” says Jeremy Sturgess-Smith, the co-founder and finance director of Aquis-listed Ananda Developments Plc (AQSE:ANA) whose CBD-derived lead asset, MRX1, is showing promise in chronic pain and heart disease. With a valuation of just under £16 million, you would also say Ananda has flown well below the radar given the phase II-ready status of MRX1 and pre-clinical data shared with the market last week. A Nasdaq-listed company with those credentials might expect to have an additional nought on the end of that figure above (at the least). But this is the hard reality of UK life science at the moment – drug development groups of Ananda’s ilk just don’t receive the recognition or funding of their American counterparts. It has led to a handful of small innovators, including Redx Pharma and C4X Discovery, to quit the public arena.  Badge of honour That’s not something Ananda is... More at #Proactive #ProactiveInvestors http://ow.ly/FnG5105zpX1

The #JCA is now live! Today marks a momentous day in international #HTA with the implementation of the Joint Clinical Assessment (JCA). This initiative represents one of the most significant shifts in HTA practice to date, with ambitious goals to harmonise processes, enhance #patientaccess, and reduce duplication of efforts across #Europe.   These ambitious plans also raise questions about capacity, uncertainty and efficiency. P4A’s insights from HTA agencies like #Sweden’s #TLV highlight the resource demands and uncertainties of aligning joint HTA outputs with national frameworks, illustrating the challenges of achieving the meaningful harmonization of processes that has been envisaged for JCA and therefore potentially negatively impacting patient access to oncology drugs and #ATMPs. Other products with #orphandesignation will continue to go through   For developers of oncology drugs and ATMPs, the implications are even more profound. As the market for orphan medicines becomes increasingly constrained, ensuring that evidence requirements are met will be critical to achieving sustainable access. At P4A, we are committed to supporting developers navigate this new landscape. With one of the biggest concerns of JCA being the selection of #PICOs and timeline for submitting the evidence package to address the selected PICOs, we have developed the #PICO+ simulation model which is specifically designed to prepare for the evidence requirements for oncology and ATMPs. This will help developers identify the potential PICOs that will be requested in the JCA, allowing for evidence preparation while optimising resources.   Commentary to date on JCA has largely focused on the challenges—from capacity issues to alignment complexities. Now that it is in effect, it is time to shift focus and embrace the possibilities it brings. If the best-case scenario plays out, this initiative has the potential to drive meaningful improvements for #patients across Europe. With collaboration, innovation, and the right tools, we can make the most of this new era of joint HTA.   #JointHTA #JCA #EUHTA #RareDiseases #Innovation #Healthcare #P4Ainsights #Partners4Access

Why Pharma and DTx Partnerships are a Match Made in Healthcare Heaven 🤝💊 In the world of Digital Therapeutics (DTx), the right pharma partner is like the perfect match on a dating app—you swipe right, and suddenly things get serious. Here’s why DTx companies need these partnerships: 🌍 Bigger Reach: Pharma knows how to navigate the healthcare maze and get DTx solutions in front of the right people (aka, patients). They’ve got the connections! 🚀 R&D Boost: Pharma brings decades of clinical expertise to the table. Together, it’s like having an R&D dream team with more data and resources to speed up innovation. 📖 Navigating Regulations: Let's face it, regulations can be a nightmare. Pharma knows the ropes, making approvals and reimbursements way less scary. 🤝 Trust Factor: People trust pharma (well, mostly), so a pharma-backed DTx solution is easier for doctors and patients to embrace. 🥳 Power Couples We Love: Click Therapeutics, Inc. & Boehringer Ingelheim (DTx for schizophrenia). Akili & Shionogi Inc. (U.S.): Collaborating on ADHD digital therapeutics in Japan. CureApp, Inc. & Novartis: Partnering to deliver DTx for smoking cessation. Twill & Sanofi (collaborating on DTx for multiple sclerosis). Comment if there any other exciting partnerships out there you wanted to shout about!